Helping Patients Get TIGLUTIK

TIGLUTIK is only available from  Anovo Specialty Pharmacy.

ITF Pharma, the maker of TIGLUTIK, recognizes the important medical need that TIGLUTIK fulfills for many people with ALS. This is why AnovoRx is our exclusive Specialty Pharmacy. Anovo is different from local pharmacies. Anovo’s focus is intentionally centered on the unique needs of patients and their TIGLUTIK therapy.

Anovo not only works with the prescriber’s office to help coordinate the TIGLUTIK ordering process with the patient’s insurance company, but they also do a lot more. They are available 24 hours per day, 7 days per week, to answer any questions about TIGLUTIK. Once all of the insurance paperwork is completed, Anovo calls the patient or their caregiver to confirm their shipment of TIGLUTIK, which is sent directly to the patient’s home.  The Caller ID will be AnovoRx Group: (901) 201-5470.

Benefits of Anovo Specialty Pharmacy

Administrative support

Anovo provides ongoing assistance to patients and their doctor’s office staff with expert handling of the necessary paperwork and insurance requirements

Direct-to-patient convenience

TIGLUTIK is shipped from Anovo directly to your home at no extra charge

Ongoing assistance

Anovo reminds patients about their refills of TIGLUTIK and manages insurance and challenges with reimbursement

Comprehensive communication

Knowledgeable and highly trained staff are available to answer any TIGLUTIK treatment-related questions – 24 hours per day, 7 days per week

No questions left unanswered

If you have any questions, you are encouraged to call Anovo at (844) 763-1198 – they are there to help



TIGLUTIK is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS).

Important Safety Information


TIGLUTIK is contraindicated in patients with a history of severe hypersensitivity reactions to riluzole or to any of its components.

Warnings and Precautions

TIGLUTIK can cause liver injury and there have been cases of drug-induced liver injury, some of which were fatal, in patients taking riluzole. Asymptomatic elevations of hepatic transaminases have been reported and, in some patients, have recurred upon re-challenge with riluzole. Maximum increases in ALT occurred within 3 months after starting riluzole. Monitor patients for hepatic injury every month for the first 3 months of treatment, and periodically thereafter; TIGLUTIK should be discontinued if there is evidence of liver dysfunction, for example, elevated bilirubin. Use of TIGLUTIK with other hepatotoxic drugs may increase the risk for hepatotoxicity.

TIGLUTIK can cause neutropenia. Cases of severe neutropenia (absolute neutrophil count less than 500 per mm3) within the first 2 months of riluzole treatment have been reported. Advise patients to report febrile illnesses.

TIGLUTIK can cause interstitial lung disease, including hypersensitivity pneumonitis. Discontinue TIGLUTIK immediately if interstitial lung disease develops.

Adverse Reactions

The most common adverse reactions (incidence greater than or equal to 5% and greater than placebo) of TIGLUTIK were oral hypoesthesia (29%), asthenia (19%), nausea (16%), decreased lung function (10%), hypertension (5%), and abdominal pain (5%).

Coadministration of TIGLUTIK with strong or moderate CYP1A2 inhibitors, such as ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, and zileuton, may increase the risk of TIGLUTIK-associated adverse reactions. 

Coadministration of TIGLUTIK with CYP1A2 inducers may result in decreased efficacy of TIGLUTIK.

Use in Specific Populations

Patients with mild or moderate hepatic impairment (Child-Pugh’s score A or B) had increases in AUC compared to patients with normal hepatic function. Thus, patients with mild or moderate hepatic impairment may be at increased risk of adverse reactions. Use of TIGLUTIK is not recommended in patients with baseline elevations of serum aminotransferases greater than 5 times the upper limit of normal or evidence of liver dysfunction.

Japanese patients are more likely to have higher riluzole concentrations, and thus may be at a greater risk of adverse reactions.

Please see accompanying prescribing information.

Intended for U.S. Residents Only

ITF Pharma logo

©2021 ITF Pharma Inc. All rights reserved.  TIGLUTIK is a trademark of ITALFARMACO SA 

3 Paoli Plaza, Suite C
Paoli, PA 19301 United States
Medical/Product Inquiries: 844-763-1198
EDW Pharma US Headquarters: 610-937-6172